# Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%

> **Open Intelligence Dossier** · First detected: 2026-10-29 03:40 UTC · Category: Business

## Executive Summary
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.


Outlets currently covering the story include WSJ, BioSpace, Yahoo Finance and Fierce Biotech. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| MedWatch | Genmab soars as key cancer drug succeeds in late-stage trial | [Source Link](https://news.google.com/rss/articles/CBMib0FVX3lxTFBManVSQ1dMTlJvNWx6Um9iemd2VDAzYUhuWHNsNkFENHVqLVZDbnBkeGs4RDJUSjJXOUp4cHVEeHFWUHJuWlBtLTVzQW5uSGc3ckVTOGVmOGpHVC1fOHNjNlZuODdwNWFiMnNfNFNSWQ?oc=5) |
| WSJ | Genmab Shares Soar on Success in Head and Neck Cancer | [Source Link](https://news.google.com/rss/articles/CBMi7wFBVV95cUxNUzVNa2ZhclJyR3JtTVVIakxCOEx6eUNuc3FLR3ViZTRmNk1YQ1d1V1FQeWkxYmlRNWw2Ul9WSi1uNlBSTndweWpaVnJEMmVBMThOLVk5U3FLaHJMZzMyaVZIeWhWcHN1a3l4T1hsTl9mVXFiN1dkR0o5WXFmVFVyMDlOWGdyaGdwOFVHUi15UDRET0t0empnMUp3MmFSVExmZjZxQlV1WFlVSDRma0s5UzV0MzA4b1RFdnA3aF9IRlN4UGxBbmFtOHk0SGJJSTlCUnRDaWFvc1JfZWdUWENUbDJMX1FORHJaVFF0bVFVNA?oc=5) |
| BioSpace | Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout | [Source Link](https://news.google.com/rss/articles/CBMi0AFBVV95cUxQMThiQ01VU2F5OFNFUUhOY2JqS21hVFJmSlJGbktWYjNNVEJKcDRGNGRZaVZsUF9nYkZndW1nSmdfeVlNZ0NwZUdxVzJmQk9JUTQ3cW9vY0hWYlp3MGkxSjdfaWZuMllYWV9lUUtWbDhWN3o2TGVwejd3VElWMmVqTndMWmJ0aGFiY0dWYnV0LVYtR0hCQVpGTlRMR3ZTa2VUOGx0bE5pU0Ezc2Fsc3RFTjZ2Z3hwU3JxMlc3bmRTNlVLSHR1d3hHNDE4SjIyNENM?oc=5) |
| Yahoo Finance | GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know | [Source Link](https://news.google.com/rss/articles/CBMilAFBVV95cUxQd2NJX0o3eWt6TG9zXzA4bWNKXzVyNWhqUDl6NVVtNWlvamdUR3BDQXhJU05nYW1hQW96YmZ6ZF9ubkR6NWV4RkVzcUQ4NGdXZHBmclFiUDI4d1RPN0xzQ3BLZnNZb2E0TTBnbWNPZi1iZkVkaWNUSWV4ejR0UGEtajhfQTBWXzFwMV9UYzMybnZYdVl0?oc=5) |
| Fierce Biotech | Genmab's $8B Merus bet delivers as bispecific combo halves risk of death in phase 3 | [Source Link](https://news.google.com/rss/articles/CBMipAFBVV95cUxOaGZDMDVVV3FNSFZqeEVzM1JaUHZfRHpHcDBqS1BFZEoxUHZfcTR1U0c0ZmFOOWczNnpKcVNWaEZWV2lBNkFrVmFXdXczN3gyRV8xT19YdmpmM0tYMTFhR0RaRlN4d2g3UVhJSVR4X3J3Ni0zUmJadE51X2M3c0duSzVpdm83VHJjMjdmMV93bkdLa2VNREFPazdNQ0lyN0pRZTdBbg?oc=5) |
| Barron's | Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50% | [Source Link](https://news.google.com/rss/articles/CBMihAFBVV95cUxPYlRvUDRDOFJwb2dGZWtNNXRXWWN0ZGV3XzNUWGk0ckR4bjV1ZmQ1c0FLZHhUYVFXQmtQNndzR3lHQkRUNWo3WC0yNWFWZjBjNFUzc0t6ZVh4ZDNEbGZZVHF3eFV2dUlhX19BOFZ3aWhhamFYYUc5bFpOYVhpWGhfVkdDMWs?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-10-29/genmab-stock-surges-to-record-high-as-cancer-drug-slashes-risk-of-death-by-50*